A Clinical Investigation Into the Association of an Impaired Skin Barrier and Infant and Toddler Sensitive Skin
NCT ID: NCT07225166
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2025-10-01
2025-11-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Skin Barrier Assessment in Pregnancy and at Birth
NCT04445298
Skin Characteristics of Parents of Food Allergic Pediatric Patients
NCT04198753
Exploring the Influence of Elevated CO2 on Allergic Skin
NCT06244524
Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers
NCT03625219
Characterization of Chronic Hand Eczema
NCT05026554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-Sensitive Skin Group
* 5-8 babies that are 3 to 6 months old
* At least 5 babies that are 7 to 12 months old
* At least 10 toddlers that are 13 to 36 months old
Expert Clinical Grading
The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):
\- Visual Dryness, Tactile Surface Roughness, Erythema.
Instrumental Measurements
The following procedures will be conducted on the child subject:
* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements
Parental Questionnaires
The following questionnaires will be given to the parent subject to answer:
* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines
Biomarker Measurements
The following procedures will be conducted on the child subject:
* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)
Sensitive Skin Group
* 5-8 babies that are 3 to 6 months old
* At least 5 babies that are 7 to 12 months old
* At least 10 toddlers that are 13 to 36 months old
Expert Clinical Grading
The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):
\- Visual Dryness, Tactile Surface Roughness, Erythema.
Instrumental Measurements
The following procedures will be conducted on the child subject:
* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements
Parental Questionnaires
The following questionnaires will be given to the parent subject to answer:
* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines
Biomarker Measurements
The following procedures will be conducted on the child subject:
* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Expert Clinical Grading
The expert grader will separately assess each child subject's face and body (right and left volar forearms combined, right and left leg combined, torso) for each of the parameters below according to the following 4-point scales (half points are allowed):
\- Visual Dryness, Tactile Surface Roughness, Erythema.
Instrumental Measurements
The following procedures will be conducted on the child subject:
* Corneometer measurements
* Tewameter measurements
* Skin pH Meter measurements
Parental Questionnaires
The following questionnaires will be given to the parent subject to answer:
* Questionnaire: Reaction to Environmental, Chemical, and Mechanical Stimuli
* Questionnaire: Medical/Family History Questionnaire
* Questionnaire: Bathing and Skincare Routines
Biomarker Measurements
The following procedures will be conducted on the child subject:
* D-Squame skin sampling (for corneocyte visualization and lipid analysis)
* Microbiome sampling
* D-Squame skin sampling (for inflammatory proteins)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Generally, in good health based on medical history reported by the parent subject.
2. Intends to complete the study and is willing and able to follow the subject responsibilities and undergo necessary testing procedures (tape stripping for baby subjects) and answer multiple questionnaires.
Child subject:
3. Males and females aged 3 months-old up to 36 months-old (inclusive), targeting to complete with:
Sensitive Skin Cohort (cohort 1): at least 30 child subjects in the 3 months-old up to 36 months-old range with 100% HCP diagnosed sensitive skin or parent-reported sensitive skin, and as defined as parent subjects who respond "Yes" to the Yes/No question "Do you believe your child has sensitive skin?"
Non-Sensitive Skin Cohort (cohort 2): at least 30 child subjects in the 3 months-old up to 36 months-old age range with 100% having normal skin, has never been diagnosed with sensitive skin by a HCP, and as defined as parent subjects who respond "No" to the Yes/No question "Do you believe your child has sensitive skin?"
4. Has parent-reported natural skin tone "pale/fair to light white," "white to light beige," "beige to light tan/light olive," "medium tan/medium olive to light brown," "medium brown to dark brown," "darkest brown to darkest black", with every effort made to complete with at least 1 child subject for each skin tone per cohort.
Parent subject:
5. Is at least 18 years old.
6. Is the primary caregiver and legal guardian of the child subject and is willing and able to present proof of legal guardianship (e.g. birth certificate/hospital discharge paperwork along with valid ID of legal guardian, etc.).
7. Is able to read, write, speak, and understand English.
8. Has signed the Consent for Photo Release and ICD including a Health Insurance Portability and Accountability Act (HIPAA) disclosure.
9. Intends to complete the study and is willing and able to follow all study instructions.
10. Parent subjects must agree to discontinue child's current face/body washes and face/body lotions for 24 hours prior to their study visit.
Exclusion Criteria
1. Is using Systemic or topical over-the-counter (OTC) or prescription medications that, in the Investigator's judgement, will affect skin condition or interfere with study evaluation. (Use of acetaminophen as needed is acceptable if it was instructed by the baby's pediatrician. Child vitamins are allowed.)
2. Is using topical steroids within 2 weeks before Visit 1.
3. Has Type 1 or Type 2 diabetes(reported by the parent) or is taking insulin or another anti-diabetic medication.
4. Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
1. Immunosuppressive or steroidal drugs within 2 months before Visit 1
2. Non-steroidal anti-inflammatory drugs within 5 days before Visit 1
3. Antihistamines within 2 weeks before Visit 1
4. If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Investigator should be consulted to consider the impact of the specific medication on subject safety and/or the study results.
5. Has a history of or a concurrent health/other condition/situation which may put the child subject at significant risk, confound the study results, or interfere significantly with the subject pair's participation in the study, as determined by the Investigator or designee.
6. Has a history of skin cancer.
7. Is simultaneously participating in another study involving product usage or skin sampling for the duration of the study or has participated in another study involving product usage or skin sampling within 14 days prior to Visit 1.
8. Has used new facial and body products and/or brands two weeks prior to Visit 1.
9. Is an immediate family member of the Investigator, Study Site, or Sponsor.
10. Presents with a skin condition that may confound the study results, increase risk to the subject, or influence the outcome of the study (e.g., psoriasis, eczema, atopic dermatitis, cutaneous xerosis, or active skin cancer), as determined by the Investigator or designee.
Parent subject:
11. Is simultaneously participating in another study.
12. Is an employee/contractor of the Study Site or Sponsor or immediate family member of the PI, Study Site, or Sponsor.
3 Months
36 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kenvue Brands LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SGS North America, Inc. - Dallas Research Center
Richardson, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS2025SK100263
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.